<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sidiras P</submitter><funding>Fonds Erasme pour la Recherche Médicale’</funding><funding>Radio-télévision belge de la Communauté française (RTBF)</funding><funding>Fonds de la recherche scientifique-FNRS</funding><funding>King Baudouin Foundation</funding><pagination>2826-2834</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258537</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>61(7)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA.&lt;h4>Methods&lt;/h4>Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs.&lt;h4>Results&lt;/h4>Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection o</pubmed_abstract><journal>Rheumatology (Oxford, England)</journal><pubmed_title>Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.</pubmed_title><pmcid>PMC9258537</pmcid><funding_grant_id>CAP48</funding_grant_id><pubmed_authors>Lechanteur J</pubmed_authors><pubmed_authors>Imbault V</pubmed_authors><pubmed_authors>Sidiras P</pubmed_authors><pubmed_authors>Durez P</pubmed_authors><pubmed_authors>Rasschaert J</pubmed_authors><pubmed_authors>Sokolova T</pubmed_authors><pubmed_authors>Gangji V</pubmed_authors><pubmed_authors>Communi D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Human carbamylome description identifies carbamylated α2-macroglobulin and hemopexin as two novel autoantigens in early rheumatoid arthritis.</name><description>&lt;h4>Objectives&lt;/h4>Anti-carbamylated protein antibodies (anti-CarPAs) are present in RA sera and have been associated with erosive disease. The exact targets of anti-CarPAs in vivo are currently not well known; we used a proteomic approach on serum and SF of RA patients to assess the human carbamylome and to identify carbamylated autoantigens as potential biomarkers in early RA.&lt;h4>Methods&lt;/h4>Mass spectrometry was performed on SF and serum from RA patients. Carbamylated proteins present in both sample types were selected as candidate autoantigens for the establishment of ELISAs. A cohort of early RA patients was tested for positivity for specific anti-CarPAs.&lt;h4>Results&lt;/h4>Eleven novel carbamylated proteins were identified, and five were selected as potential autoantigens for detection o</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-25T20:59:43.067Z</modification><creation>2022-07-23T08:44:53.935Z</creation></dates><accession>S-EPMC9258537</accession><cross_references><pubmed>34788409</pubmed><doi>10.1093/rheumatology/keab838</doi></cross_references></HashMap>